3D Cell Culture Market Size to Exceed USD 32.42 Bn by 2032

The 3D Cell Culture Market, estimated at USD 7.44 Bn in 2025, is expected to exhibit a CAGR of 23.4% and reach USD 32.42 Bn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

The rising prevalence of cancer and infectious diseases are expected to propel the growth of the global 3D cell culture market over the forecast period. The rising demand for 3D cell culture for the treatment of various diseases, owing to the increasing prevalence of cancer and infectious diseases is expected to boost the 3D cell culture market growth over the forecast period. For instance, according to a World Health Organization (WHO) report published on February 3, 2025, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2025, or nearly one in six deaths with the most common cancers are breast, lung, colon and rectum, and prostate cancers.

Global 3D Cell Culture Market - Impact of Coronavirus (COVID-19) Pandemic

3D cell culture techniques are becoming increasingly popular as versatile and biologically relevant research models to support the fight against COVID-19. Stem cells are emerging as a preferred model to predict which type of cell can be permissive to certain types of viruses, providing insights to scientists and clinicians and offering advantages over the limited resources of biobanks for human tissue, in vitro Petri dish cultures, or animal models.

Several companies are supporting research and development activities using 3D cell cultures for the development of new screening and therapy platforms. For example, Corning Incorporated highlighted its latest technologies that support the advancement of 3D cell culture, automation, and drug discovery as new solutions to support the evolving industry needs such as COVID-19 response, disease models, and drug discovery at the 2025 virtual Society for Laboratory Automation and Screening (SLAS) conference 1. In November 2025, Biogelx, a biomaterials company aimed to provide U.K.-Spanish research groups working on COVID-19 vaccines with advanced 3D cell culture to mitigate risks arising during drug development and testing processes. Biogelx is committed to supporting the scientific community working on COVID-19 vaccine research.

In October 2020, a study published in Cell Press Journal reported that a team of scientists from the U.K. and South Korea turned to organoids - ‘miniorgans’ grown in three dimensions to mimic the behavior of tissue and organs. The scientists were able to grow self-organizing alveolar-like 3D structures that mimic the behavior of key lung tissue for understanding how COVID-19 affects the lungs. The mini-lungs grown from tissue donated to Cambridge hospitals have provided a team of scientists with important insights into how COVID-19 damages the lungs. In new work, the researchers explained the mechanisms underlying SARS-CoV-2 infection and the early innate immune response in the lungs.

Global 3D Cell Cultures Market: Key Developments

In February 2022, OPTI-STEM Consortium, led by CDMO Cell-Easy, a biotechnology company in Toulouse, France received US$ 7.8 million from the French government and Bpifrance as well as US$900,000 from the Occitanie region to democratise access to cell therapy in France and Europe.

In November 2021, Cellaria Inc, a scientific innovator with breakthrough tools for cancer research, announced the availability of a series of new products, including a panel of cell culture media optimized to grow clinically relevant cell types, an extra-cellular fully defined neutral collagen matrix (ECM), and validated protocols for a scalable and reproducible testing of small patient cohorts for screening of novel drug compounds.

In November 2021, EdiGene, Inc., a global biotechnology company, announced that it has entered into a research collaboration with University of Wisconsin–Madison as part of the company’s effort of translating proprietary LEAPER RNA editing technology into in vivo therapies.

Browse 34 Market Data Tables and 36 Figures spread through 172 Pages and in-depth TOC on “Global 3D Cell Culture Market”- Forecast to 2030, by Technology (Extracellular Matrices or Scaffolds, Bioreactors, Gels, Scaffold-free Platforms, and Microchips), by Application (Research, Drug Discovery, Tissue Engineering, Clinical Applications, and Stem Cell Biology), by End User (Research Labs & Institutes, Biopharmaceutical Industry, Hospitals And Diagnostic Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/3d-cell-culture-market-534

Key Takeaways of the Global 3D Cell Culture Market:

• The global 3D cell culture market is expected to exhibit a CAGR of 23.4% during the forecast period due to increasing product approvals and. For instance, in January 2020, Visikol, a 3D cell culture characterization and analysis company, announced the launch of OpenLiver 3D cell culture models to accelerate drug discovery. Visikol expanded its service offering through the introduction of its own liver 3D cell culture models.
• Among application, the drug discovery segment is estimated to exhibit higher CAGR in the global 3D cell culture market over the forecast period. Ongoing research in the development of different types of 3D cell culture to assist drug development is expected to foster the growth of this segment.
• Among end user, the biopharmaceutical industry segment is estimated to hold largest market share in the global 3D cell culture market over the forecast period. Due to high benefits of the 3D cell cultures in the biopharmaceutical industry, companies are focusing on service launches, to provide 3D cell culture procedures to customers present in the biopharmaceutical industry.
• On the basis of region, North America is estimated to exhibit higher CAGR in the global 3D cell culture market over the forecast period. The market in Asia Pacific is expected to witness significant growth, owing to increasing healthcare expenditure.
• The major players operating in the global 3D cell culture market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Lonza, Merck KGaA, 3D Biotek LLC, 3D Biomatrix, Inc., 3D Biomatrix, Inc., and REPROCELL Inc.